1645P A phase Ib study to evaluate the safety, tolerability and efficacy of the combination of encorafenib, binimetinib and palbociclib in patients with BRAF-mutant metastatic melanoma (CELEBRATE).
Saved in:
| Title: | 1645P A phase Ib study to evaluate the safety, tolerability and efficacy of the combination of encorafenib, binimetinib and palbociclib in patients with BRAF-mutant metastatic melanoma (CELEBRATE). |
|---|---|
| Authors: | Chan, J.1 (AUTHOR), Dixon Douglas, J.R.1 (AUTHOR), Xie, J.2 (AUTHOR), Khoo, C.1 (AUTHOR), Soon, J.1 (AUTHOR), Weppler, A.1 (AUTHOR), Parente, P.3 (AUTHOR), Shackleton, M.4 (AUTHOR), Kee, D.5 (AUTHOR), McArthur, G.1 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS976-S976. 1p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 189420063 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: 1645P A phase Ib study to evaluate the safety, tolerability and efficacy of the combination of encorafenib, binimetinib and palbociclib in patients with BRAF-mutant metastatic melanoma (CELEBRATE). – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Chan%2C+J%2E%22">Chan, J.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Dixon+Douglas%2C+J%2ER%2E%22">Dixon Douglas, J.R.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Xie%2C+J%2E%22">Xie, J.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Khoo%2C+C%2E%22">Khoo, C.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Soon%2C+J%2E%22">Soon, J.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Weppler%2C+A%2E%22">Weppler, A.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Parente%2C+P%2E%22">Parente, P.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Shackleton%2C+M%2E%22">Shackleton, M.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kee%2C+D%2E%22">Kee, D.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22McArthur%2C+G%2E%22">McArthur, G.</searchLink><relatesTo>1</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2025 Supplement 2, Vol. 36, pS976-S976. 1p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=189420063 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.annonc.2025.08.2273 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 1 StartPage: S976 Titles: – TitleFull: 1645P A phase Ib study to evaluate the safety, tolerability and efficacy of the combination of encorafenib, binimetinib and palbociclib in patients with BRAF-mutant metastatic melanoma (CELEBRATE). Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Chan, J. – PersonEntity: Name: NameFull: Dixon Douglas, J.R. – PersonEntity: Name: NameFull: Xie, J. – PersonEntity: Name: NameFull: Khoo, C. – PersonEntity: Name: NameFull: Soon, J. – PersonEntity: Name: NameFull: Weppler, A. – PersonEntity: Name: NameFull: Parente, P. – PersonEntity: Name: NameFull: Shackleton, M. – PersonEntity: Name: NameFull: Kee, D. – PersonEntity: Name: NameFull: McArthur, G. IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 09 Text: 2025 Supplement 2 Type: published Y: 2025 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 36 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |
